A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
This research is looking into a new treatment called Ulviprubart for Inclusion Body Myositis (IBM), a rare muscle condition. It's a 'Phase 2/3' study, meaning it's still in the stages of checking if the medicine works well and is safe. The study compares Ulviprubart to a 'placebo' (a dummy treatment with no active medicine) to see its effects. The main goal is to find out if Ulviprubart helps people with IBM with their daily activities and muscle strength over about 18 months. Researchers will also be carefully watching for any side effects. This study is designed to gather important information that could potentially lead to a new treatment option for people living with IBM.
At a glance
What is this study about?
Inclusion Body Myositis (IBM) is a rare condition that causes muscles to become weak and waste away over time. This can make everyday tasks like walking, climbing stairs, or even swallowing more difficult. Because it's a condition that can have a big impact on daily life, doctors and scientists are constantly working to find new ways to help manage it and improve the lives of those affected.
This particular study is like a two-part investigation into a new medicine called Ulviprubart. The first part (Phase 2) helps work out the best dose and confirms the medicine is generally safe. The second part (Phase 3) then looks at a larger group of people to robustly check if the medicine is truly effective and safe over a longer period.
The main aim of this study is to see if Ulviprubart can make a positive difference in how people with IBM manage their daily lives and their muscle strength. Researchers will use special scales and tests to measure any changes. They will also be meticulously tracking any side effects to make sure the medicine is not only effective but also well-tolerated. Finding new and better treatments for IBM is very important, and studies like this help move us closer to that goal.
Key takeaways
- Tests a new medicine (Ulviprubart) for Inclusion Body Myositis (IBM).
- Compares Ulviprubart to a dummy treatment (placebo) over 76 weeks.
- Aims to check if the medicine improves daily activities and muscle strength.
- Also carefully monitors for any side effects and overall safety.
- Open to adults aged 18 and over, both men and women.
- Participation could help advance understanding and treatment of IBM.
Who may be eligible?
To be able to take part in this study, you would need to be at least 18 years old. There's no upper age limit for joining.
Both men and women are welcome to participate in this research. The study needs a wide range of participants to get a clear picture of how the new medicine works across different people.
There will be other specific health requirements that your doctor would check to make sure the study is a good fit for you and safe for you to join. These are in place to protect your well-being and ensure that the study results are as accurate as possible.
- Are you 18 years old or older?
- Do you have a diagnosis of Inclusion Body Myositis?
- Are you able to attend regular clinic visits?
- Are you comfortable with the possibility of receiving a dummy treatment (placebo)?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you would be given either the new medicine, Ulviprubart, or a dummy treatment (placebo). Neither you nor your study doctor would know which one you are receiving – this is to make sure the results are fair and unbiased. The main treatment period will last for about 76 weeks, which is roughly a year and a half.
Throughout the study, you would have regular visits to the clinic. At these visits, doctors and nurses would perform various assessments. This includes checking your muscle strength, your ability to do daily activities, and looking for any changes in your overall health. They will also carefully record any side effects you might experience.
After the main treatment period, there will be a follow-up period to see how you are doing. The total time you would be involved in the study, including follow-up, would be fully explained to you before you agree to participate.
Potential risks and benefits
Locations (3)
- —Belgium
- —Germany
- —France
Common questions
What is Ulviprubart?
Ulviprubart is a new medicine being tested to see if it can help people with Inclusion Body Myositis (IBM).
What does 'placebo-controlled' mean?
It means some people in the study will get the new medicine, and others will get a dummy treatment (placebo) with no active ingredients. This helps doctors see if the medicine is truly working.
How long will I be in the study?
The main treatment part of the study lasts for about 76 weeks, which is around a year and a half. There will also be a follow-up period after that.
What will researchers be looking for?
They will mainly be looking to see if Ulviprubart helps improve your muscle strength and your ability to carry out daily activities. They will also carefully check for any side effects.
Can I choose which treatment I get?
No, you won't be able to choose. It's a 'double-blind' study, meaning neither you nor your doctors will know if you're getting the active medicine or the placebo, to ensure fair results.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.